Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT05342350 Recruiting - Clinical trials for Hepatocellular Carcinoma

International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy

STOP-HCC
Start date: April 15, 2022
Phase:
Study type: Observational [Patient Registry]

This study has two purposes. One is to conduct a phase IV biomarker validation study in which the investigators will prospectively survey a cohort of patients at risk for liver cancer using semi-annual abdominal ultrasound and GALAD Score for 5 years. The GALAD score is a serum biomarker-based panel that can aid in early detection among patients with a high risk for liver cancer. One is to establish a bio-repository of longitudinally collected bio-specimens from patients with fibrosis/cirrhosis as a reference set for future research.

NCT ID: NCT05339321 Recruiting - Clinical trials for Hepatocellular Carcinoma

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Start date: April 14, 2021
Phase: Phase 1
Study type: Interventional

Adoptive cell therapy with TCR-T cells targeting HBV antigens represents an innovative opportunity for treatment of HBV-related HCC. SCG101 is a genetically modified autologous TCR-T cell therapy with a natural high-avidity TCR directed towards the HLA-A*02-restricted HBsAg peptide. This is a phase 1 clinical study of SCG101 alone and with PD-1/PD-L1 checkpoint inhibitors in HBV-related HCC.

NCT ID: NCT05332821 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

CHANCE2201
Start date: December 28, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage hepatocellular carcinoma (HCC).

NCT ID: NCT05332496 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

CHANCE2202
Start date: December 28, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage hepatocellular carcinoma (HCC).

NCT ID: NCT05331911 Recruiting - Clinical trials for Hepatocellular Carcinoma

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors

Start date: April 26, 2022
Phase: Phase 4
Study type: Interventional

This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma. The study will enroll approximately 500 volunteers to compare the progression-free or overall survival in patients undergoing elective partial hepatectomy for primary liver tumors between propofol and sevoflurane for the maintenance of anesthesia.

NCT ID: NCT05323201 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Start date: February 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.

NCT ID: NCT05320692 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Start date: August 9, 2022
Phase: Phase 3
Study type: Interventional

A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.

NCT ID: NCT05317819 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC

NCT ID: NCT05304481 Recruiting - Clinical trials for Hepatocellular Carcinoma

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

Start date: May 14, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).

NCT ID: NCT05304234 Recruiting - Clinical trials for Hepatocellular Carcinoma

Liver Cancer Disparities in American Indian and Alaska Native Persons

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.